International Stem Cell to Launch Advanced Joint Supplement

International Stem Cell (OTCQB:ISCO) a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Company plans to launch its advanced joint supplement, designed to potentially reduce joint pain associated with osteoarthritis, in Q3 2018.

As quoted in the press release:

The initial launch will be geared towards existing Lifeline Skin Care customers, who represent the target demographic and who have been loyal to the brand. The Company will evaluate the results of the soft launch and determine which additional sales channels (i.e. retail, doctors’ offices) it plans to pursue outside of the online space.

“The research our scientific team recently published in the Journal of Tissue Engineering and Regenerative Medicine has illustrated that by combining the right ingredients, mesenchymal stem cells possess the remarkable potential to repair human cartilage tissue,” commented Russell Kern, PhD, ISCO’s Executive Vice President and Chief Scientific Officer.  “Our scientists have developed a scalable, unique joint supplement designed to potentially reduce joint wear-and-tear, alleviate muscle cramps, and relieve stressed tendons,” he continued.

Click here to read the full press release.